FDA signs off on Lilly’s new antibody drug, bebtelovimab, which is effective against the omicron variant

FDA signs off on Lilly’s new antibody drug, bebtelovimab, which is effective against the omicron variant
kdunleavy
Fri, 02/11/2022 – 17:32